Cancer Therapeutics: Technology, Discovery, and Targeted Delivery Program

癌症治疗：技术、发现和靶向治疗项目

• 批准号: 9107361
• 负责人: CHERYL LYNN WILLMAN
• 金额: $ 7.11万
• 依托单位: UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-26 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9107361
• 关键词: Advisory Committees; Aerosols; Animal Model; Antibodies; Antineoplastic Agents; Bacteriophages; Biological; Biological Assay; Biological Models; Biology; Biomedical Engineering; Biotechnology; Blood Vessels; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Diagnostics; Cell Surface Receptors; Cells; Clinical; Clinical Investigator; Clinical Trials; Clinical Trials Network; Collaborations; Coupled; Critiques; Diagnostic Imaging; Direct Costs; Doctor of Philosophy; Drug Delivery Systems; Engineering; Evaluation; Faculty; Flow Cytometry; Foundations; Funding; G-Protein-Coupled Receptors; Goals; Grant; Human; Hydrogels; Image; Industry; Informatics; Integrins; Intellectual Property; Intervention; Intervention Trial; Investigation; Isotopes; Laboratories; Lead; Leukocytes; Libraries; Ligands; Malignant Neoplasms; Mathematics; Methods; Mission; NCI Center for Cancer Research; Nanotechnology; Neoplasm Circulating Cells; New Mexico; Normal Cell; Normal tissue morphology; Oral; Pathologic; Pathway interactions; Peer Review; Peptide antibodies; Peptides; Phage Display; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacy facility; Phase; Phase I Clinical Trials; Phosphorylation; Physicians; Population; Publications; Publishing; Recruitment Activity; Research; Research Infrastructure; Research Institute; Research Personnel; Route; Scientist; Silicon Dioxide; Technology; Therapeutic; Therapeutic Agents; Therapeutic Uses; Tissues; Translating; Translations; Tumor Tissue; United States National Institutes of Health; Universities; Virus-like particle; Work; abstracting; base; cancer cell; cancer clinical trial; cancer imaging; cheminformatics; clinical application; clinical investigation; college; combinatorial; commercialization; design; drug discovery; experience; high throughput screening; imaging agent; in vitro Model; in vivo; innovation; mathematical methods; mathematical model; medical schools; member; molecular imaging; multidisciplinary; nanoGold; nanofabrication; nanoparticle; nanoscience; novel; pre-clinical; programs; receptor; respiratory; response; small molecule; small molecule inhibitor; targeted agent; targeted delivery; treatment response; working group

CANCER THERAPEUTICS: TECHNOLOGY, DISCOVERY & TARGETED DELIVERY (CT) RESEARCH PROGRAM ABSTRACT The Cancer Therapeutics: Technology, Discovery and Targeted Delivery (CT) Research Program, led by Larry A. Sklar, PhD and Renata Pasqualini, PhD, consists of a multidisciplinary team of 43 (27 full and 16 associate members) of basic, translational and clinical investigators assembled from 5 Departments in the UNM School of Medicine, 2 in the UNM College of Engineering, the UNM College of Pharmacy, New Mexico State University, and our UNM Cancer Center (UNMCC) consortium partners: Lovelace Respiratory Research Institute (LRRI) and Sandia (SNL) and Los Alamos National (LANL) Laboratories. CT is a new UNMCC Research Program, developed through rigorous program planning and evaluation in response to the prior 2010 NCI CCSG critique and guidance from the External Advisory Committee (EAC). Building from its origins in the Cancer Biotechnology component of the former Cancer Biology & Biotechnology Program, CT has retained and acquired scientific expertise in small molecule discovery and drug repurposing, combinatorial targeting of peptide and antibody phage display libraries, nanoparticle and virus-like particle (VLP)-based drug delivery, as well as imaging and isotopes. During the prior funding period (from 1/1/10 to 9/1/2014), CT program members published 336 original peer-reviewed articles and reviews (37% intra-programmatic and 24% inter-programmatic) and participated in 6 investigator-initiated trials. As of 9/1/14, CT funding is $16,076,676 in annual direct costs, of which $14,196,182 is peer-reviewed direct funding and $3,105,330 is from the NCI. Dr. Sklar is an expert in leukocyte biology and drug discovery and/or repurposing while Dr. Pasqualini is an expert in vascular targeting whose pivotal work in vivo with phage display has led to extensive pre-clinical and clinical applications; both leaders are experienced in translation and commercialization. CT has contributed to the bulk of UNMCC intellectual property as well as 10 biotechnology or pharmaceutical start-up companies. The Program benefits from the technological expertise in partnerships among the UNMCC, LRRI, SNL and LANL. Through the strategic recruitment of new talented faculty and infrastructure reorganization, the CT translational pipeline is expanding through: i) small molecule discovery and drug repurposing, flow cytometry technology and cheminformatics; ii) combinatorial targeting through selection of peptide and antibody phage display libraries; iii) targeted ligand-directed delivery coupled to material nanofabrication, predictive mathematical methodology, and molecular imaging; and iv) early translation into clinical application. Noted multidisciplinary, multi-investigator programmatic grants held by CT members include large NIH, NCI and DOD funds supporting translational investigations and clinical interventions. Recent physician-scientist and clinical investigator recruits will lead the current and planned portfolio of early investigator-initiated clinical trials. CT's overall goal is to discover, develop and translate innovative platform technologies into cancer diagnostic and therapeutic applications by using bioengineering, biotechnology, nanotechnology, phage display, mathematics and informatics as the basis for early interventional clinical trials.

癌症治疗：技术、发现和靶向治疗（CT） 研究计划 摘要 癌症治疗：技术，发现和靶向输送（CT）研究计划，由拉里 A. Sklar博士和Renata Pasqualini博士组成了一个由43人组成的多学科团队（27名全职人员和16名助理 成员）的基础，翻译和临床研究人员聚集在5个部门在UNM学校的 医学，2在UNM工程学院，UNM药学院，新墨西哥州州立大学， 我们的UNM癌症中心（UNMCC）联盟合作伙伴：Lovelace呼吸研究所（LRRI） Sandia（SNL）和Los Alamos National（LANL）实验室。CT是一个新的UNCC研究项目， 根据2010年NCI CCSG的评论，通过严格的计划规划和评估开发 和外部咨询委员会（EAC）的指导。从癌症生物技术的起源开始 作为前癌症生物学和生物技术计划的组成部分，CT保留并获得了科学的 在小分子发现和药物再利用，肽和抗体组合靶向方面的专业知识 噬菌体展示文库、基于纳米颗粒和病毒样颗粒（VLP）的药物递送，以及成像和 同位素在上一个资助期间（从1/1/10到9/1/2014），CT计划成员发表了336篇原创文章， 同行评审的文章和评论（37%方案内，24%方案间），并参加了6个 发起的试验。截至2014年9月1日，CT的年度直接费用为16，076，676美元，其中14，196，182美元 是同行评审的直接资助，3，105，330美元来自NCI。Sklar博士是白细胞生物学专家， 药物发现和/或再利用，而Pasqualini博士是血管靶向方面的专家， 体内噬菌体展示已经导致了广泛的临床前和临床应用;两位领导者都经验丰富， 翻译和商业化。CT为UNCC的大部分知识产权以及 10家生物技术或制药初创公司。该计划受益于技术专长 在联合国赔偿委员会、LRRI、SNL和LANL之间建立伙伴关系。通过战略性招聘新人才 随着教师和基础设施的重组，CT翻译管道正在通过以下方式扩展：i）小分子 发现和药物再利用，流式细胞术技术和化学信息学; ii）组合靶向 通过选择肽和抗体噬菌体展示文库; iii）靶向配体定向递送， 材料纳米纤维、预测数学方法学和分子成像;以及iv）早期翻译 临床应用。注意到CT成员持有的多学科、多研究者方案赠款 包括NIH、NCI和国防部大型基金，用于支持转化研究和临床干预。最近 新招募的医生-科学家和临床研究者将领导目前和计划中的早期 制药商发起的临床试验。CT的总体目标是发现，开发和翻译创新平台 通过使用生物工程，生物技术， 纳米技术、噬菌体展示、数学和信息学作为早期干预性临床试验的基础。